EPIGENETIC CLOCK DEVELOPMENT FOUNDATION

EIN: 851457272 501(c)(3) Medical Research

TORRANCE, CA

Total Revenue
$2,885,392
Total Expenses
$3,453,461
Total Assets
$954,701
Net Assets
$8,796
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
2020
Legal Domicile
CA
Principal Officer
ROBERT BROOKE
Phone
8189213980
Tax Period
2023-01-01 to 2023-12-31

EPIGENETIC CLOCK DEVELOPMENT FOUNDATION, founded in 2020, is a community nonprofit in the Medical Research sector that reported $2.9M in total revenue in fiscal year 2023. Revenue decreased 20% compared to the prior year. Expenses of $3.5M exceeded revenue, resulting in a 20% operating deficit.

Mission

THE CLOCK FOUNDATION WAS FORMED FOR THE SPECIFIC AND PRIMARY PURPOSE OF CONDUCTING MEDICAL RESEARCH ON AGING AND AGE-RELATED DISEASES. DEVELOPING THE EPIGENETIC AGING CLOCK INTO A USEFUL TECHNOLOGY WILL REQUIRE MEDICAL RESEARCH ON AGING AND AGE-RELATED DISEASES. CONSEQUENTLY, THE ACTIVITY WILL ADVANCE CLOCK FOUNDATION'S SPECIFIC PURPOSE OF CONDUCTING MEDICAL RESEARCH ON AGING AND AGE-RELATED DISEASES. IF THE MEDICAL RESEARCH OF THE CLOCK FOUNDATION IS SUCCESSFUL AND THE FDA APPROVES THE CLOCK FOUNDATION'S TESTING METHOD, MANY NEW DRUGS OR TREATMENTS THAT ARE ABLE TO REVERSE EPIGENETIC AGING COULD THEN BE FORMALLY APPROVED BY THE FDA FOR THE TREATMENT OF AGING AND FOR USE IN PREVENTATIVE MEDICINE.

Program Service Accomplishments

Program 1
Expenses: $95,167 Revenue: $33,600

INTERNAL RESEARCH PROGRAM:SINCE INCEPTION WE HAVE FOCUSED ON DEVELOPMENT OF EPIGENETIC CLOCKS AS A KEY ENABLING TECHNOLOGY FOR THE FIELD. WE ARE A SMALL TEAM OF DEDICATED RESEARCHERS, AND THIS YEAR...

Read more

INTERNAL RESEARCH PROGRAM:SINCE INCEPTION WE HAVE FOCUSED ON DEVELOPMENT OF EPIGENETIC CLOCKS AS A KEY ENABLING TECHNOLOGY FOR THE FIELD. WE ARE A SMALL TEAM OF DEDICATED RESEARCHERS, AND THIS YEAR HIRED ADDITIONAL PART-TIME OPERATIONAL, ADMIN, AND FINANCE STAFF, ALONG WITH A NEW RESEARCH ASSOCIATE. WE CONTINUED TO WORK CLOSELY WITH OUR SCIENTIFIC ADVISORS, ESPECIALLY ON DEVELOPMENT OF NOVEL TESTING APPROACHES. THE HORVATH MAMMALIAN ARRAY, A KEY ENABLING TECHNOLOGY FOR TRANSLATIONAL AGING RESEARCH, WAS PUBLISHED IN NATURE COMMUNICATIONS, WITH ADDITIONAL PAPERS PUBLISHED IN 2023 IN SCIENCE AND NATURE AGING. ADDITIONAL PAPERS HAVE BEEN RELEASED ON DOGS IN PNAS, CATS, HORSES, SHEEP, MARSUPIALS, NAKED MOLE RATS, AND MANY OTHERS. THE PAPERS DESCRIBE THE DISCOVERY OF UNIVERSAL MAMMALIAN AGING CLOCKS & EPIGENETIC PREDICTORS OF MAXIMUM LIFESPAN.

Program 2
Expenses: $2,378,281 Revenue: $2,844,903

EXTERNAL RESEARCH COLLABORATIONS: INTERVENTIONAL LONGEVITY STUDIES WE CONDUCTED MANY NEW INTERVENTIONAL STUDIES, FOR CLINICAL TRIALS AND ALSO PRECLINICAL STUDIES. THIS INCLUDES STUDIES ON...

Read more

EXTERNAL RESEARCH COLLABORATIONS: INTERVENTIONAL LONGEVITY STUDIES WE CONDUCTED MANY NEW INTERVENTIONAL STUDIES, FOR CLINICAL TRIALS AND ALSO PRECLINICAL STUDIES. THIS INCLUDES STUDIES ON PLASMAPHARESIS, YOUNG PLASMA TREATMENT, STEM CELL EXOSOMES, BONE MARROW TRANSPLANTS, UMBILICAL CORD PLASMA, ANTIRETROVIRAL TREATMENTS, AND A SENOLYTIC GENE THERAPY. WE ALSO COMPLETED ANALYSIS FOR A >1,000-PERSON LONGITUDINAL STUDY OF TESTOSTERONE TREATMENT, ANALYZING ITS EFFECTS ON ESTABLISHED CLINICAL & FUNCTIONAL AGING BIOMARKERS. MECHANISMS OF AGING STUDIES THERE WERE MANY NOTABLE MECHANISTIC STUDIES THIS PAST YEAR INCLUDING FROM THE HOCHEDLINGER LAB ON THE ROLE OF CELLULAR HETEROGENEITY IN EPIGENETIC CLOCK RESULTS, THE DALEY LAB ON LIN28'S ROLE IN REPROGRAMMING, THE LEVIN LAB ON LIMB REGENERATION, THE GLADYSHEV LAB ON BONE MARROW TRANSPLANTS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $6,600
Program Service Revenue $1,921,950
Investment Income $289
Other Revenue $956,553
TOTAL REVENUE $2,885,392

Expense Breakdown

Grants Paid $0
Salaries & Benefits $284,545
Fundraising Expenses $0
Program Expenses $3,412,523
Other Expenses $3,168,916
TOTAL EXPENSES $3,453,461

Year-over-Year Comparison

2023 2022 Change
Revenue $2,885,392 $3,593,807 -0.2%
Expenses $3,453,461 $3,391,084 +0.0%
Net Income $-568,069 $202,723 -3.8%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
3
Independent Members
3
Employees
6
Volunteers
N/A

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
1
$120,000
Total Directors
3
$240,000
Key Employees
0
$0
Highest Compensated
0
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
ROBERT BROOKE EXECUTIVE DIRECTOR 40.00
Officer Director
$120,000 $0 $120,000
STEFAN HORVATH DIRECTOR, CHAIRMAN 40.00
Director
$120,000 $0 $120,000
DEAN PRISSMAN DIRECTOR 0.00
Director
$0 $0 $0
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 No data No data No data No data
2023 $2,885,392 $3,453,461 $954,701 $-568,069
2022 $3,593,807 $3,391,084 $1,193,723 $202,723
2021 $2,774,349 $2,373,123 $708,627 $401,226
2020 $533,454 $284,532 $261,972 $248,922
Explore More Nonprofits
Top 100 Nonprofits in California Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare EPIGENETIC CLOCK DEVELOPMENT FOUNDATION with other nonprofits in California and across the country.